Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients’ experiences in Australia-Reference-Cited by-同舟云学术

Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients’ experiences in Australia

Published:2021-10 Issue: Volume:227 Page:108959
ISSN:0376-8716
Container-title:Drug and Alcohol Dependence
language:en
Short-container-title:Drug and Alcohol Dependence

Author:

Barnett Anthony,Savic Michael,Lintzeris Nicholas^ORCID,Bathish Ramez,Arunogiri Shalini^ORCID,Dunlop Adrian J.^ORCID,Haber Paul,Graham Robert,Hayes Vicky,Lubman Dan I.^ORCID

Publisher

Elsevier BV

Subject

Pharmacology (medical),Psychiatry and Mental health,Pharmacology,Toxicology

Reference31 articles.

1. Supervised methadone consumption: client issues and stigma;Anstice;Subst. Use Misuse,2009

2. National Opioid Pharmacotherapy Statistics (NOPSAD) 2017. Cat. No. HSE 199;Australian Institute of Health and Welfare,2018

3. Using thematic analysis in psychology;Braun;Qual. Res. Psychol.,2006

4. Factors influencing pharmacy services in opioid substitution treatment;Chaar;Drug Alcohol Rev.,2013

5. Subsidising patient dispensing fees: the cost of injecting equity into the opioid pharmacotherapy maintenance system;Chalmers;Drug Alcohol Rev.,2012

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Acting Injectable Buprenorphine for Opioid Use Disorder: A Qualitative Analysis of Patients’ Interpersonal Relationships during the First Year of Treatment;Substance Use & Misuse;2024-08-20

2. ‘Matters-of-concern’ associated with discontinuation of long-acting injectable buprenorphine: Findings from a longitudinal qualitative study;International Journal of Drug Policy;2024-07

3. Compared implementation of the long-acting buprenorphine treatment buvidal in four European countries;Expert Opinion on Drug Delivery;2024-05-03

4. The dynamics of more-than-human care in depot buprenorphine treatment: A new materialist analysis of Australian patients’ experiences;International Journal of Drug Policy;2024-05

5. 96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial;International Journal of Drug Policy;2024-05